Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Hologic, Inc. (NASDAQ:HOLX)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Hologic, Inc. (NASDAQ:HOLX). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Hologic stock on March 31st. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 4/1/2025.
• Sold $1,001 – $15,000 in shares of W. R. Berkley (NYSE:WRB) on 4/1/2025.
• Sold $15,001 – $50,000 in shares of GoDaddy (NYSE:GDDY) on 4/1/2025.
• Purchased $1,001 – $15,000 in shares of Ford Motor (NYSE:F) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 3/31/2025.
• Purchased $1,001 – $15,000 in shares of Boeing (NYSE:BA) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 3/31/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/31/2025.
• Sold $1,001 – $15,000 in shares of Viatris (NASDAQ:VTRS) on 3/31/2025.

Hologic Stock Up 1.5 %

Shares of NASDAQ HOLX opened at $59.31 on Thursday. The firm has a market cap of $13.31 billion, a PE ratio of 18.71, a P/E/G ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 12-month low of $57.38 and a 12-month high of $84.67. The company’s fifty day simple moving average is $63.03 and its 200 day simple moving average is $71.87. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hologic

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. West Financial Advisors LLC bought a new stake in shares of Hologic in the 1st quarter worth approximately $50,000. Czech National Bank raised its holdings in Hologic by 2.3% during the 1st quarter. Czech National Bank now owns 51,538 shares of the medical equipment provider’s stock valued at $3,184,000 after buying an additional 1,176 shares during the last quarter. Rhumbline Advisers raised its holdings in Hologic by 5.1% during the 1st quarter. Rhumbline Advisers now owns 535,348 shares of the medical equipment provider’s stock valued at $33,068,000 after buying an additional 25,822 shares during the last quarter. GAMMA Investing LLC raised its holdings in Hologic by 4,467.2% during the 1st quarter. GAMMA Investing LLC now owns 195,749 shares of the medical equipment provider’s stock valued at $120,910,000 after buying an additional 191,463 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in Hologic by 1,864.3% during the 1st quarter. Versant Capital Management Inc now owns 1,375 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 1,305 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Finally, Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $84.62.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.